Table 8.
Reproductive outcomes after FST of uterine sarcomas.
| Sarcoma | Patients, n | Pregnancies, n (%) | ART, n (%) | Miscarriages, n (%) | Preterm Deliveries, n (%) | C-Section, n (%) |
|---|---|---|---|---|---|---|
| LG-ESS | 63 | 27 (43) | 5 (19) | 2 (7) | 4 (15) | 19 (70) |
| Adenosarcoma | 19 | 4 (21) | 0 | 0 | 0 | 0 |
| STUMP | 84 | 29 (35) | 11 (38) | 2 (7) | 0 | 21 (72) |
| LMS | 7 | 3 (43) | 1 (33) | 0 | 1 (33) | 3 (100) |
| UTROSCT | 2 | 2 (100) | 0 | 0 | 0 | 1 (50) |
| Embryonal RMS of uterine cervix | 35 | 3 (9) | 0 | 0 | 0 | 1 (33) |
| Total | 210 | 68 (32) | 17 (25) | 4 (6) | 5 (7) | 45 (66) |
ART: assisted reproductive technology; C-section: caesarean section; FST: fertility-sparing treatment; LG-ESS: low-grade endometrial stromal sarcoma; LMS: leiomyosarcoma; n: number; RMS: rhabdomyosarcoma; STUMP: smooth muscle tumor of uncertain malignant potential; UTROSCT: uterine tumor resembling ovarian sex cord tumor.